Last reviewed · How we verify
Nalorphin (NALORPHINE)
Nalorphine works by binding to the mu-type opioid receptor, which can either activate or block the receptor depending on the specific configuration of the molecule.
Nalorphine, also known as NALORPHINE, is a small molecule drug that targets the mu-type opioid receptor. It belongs to the nalorphine class and was originally developed by an unknown entity. The commercial status of nalorphine is unclear, and it is not FDA-approved for any indications. As a result, there is limited information available on its safety profile and clinical use. Further research is needed to determine the potential therapeutic applications and risks associated with nalorphine.
At a glance
| Generic name | NALORPHINE |
|---|---|
| Drug class | nalorphine |
| Target | Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Mechanism of action
Think of the mu-type opioid receptor like a lock on a door. Nalorphine is a key that can either open the door (activating the receptor) or block the lock (blocking the receptor). This dual action can have different effects on the body, depending on the specific situation.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nalorphin CI brief — competitive landscape report
- Nalorphin updates RSS · CI watch RSS